PubMed:32736597
Annnotations
LitCovid-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 47-65 | CHEBI:5801 | denotes | hydroxychloroquine |
| T2 | 47-65 | DG_20 | denotes | hydroxychloroquine |
| T3 | 47-65 | CHEBI:5801 | denotes | hydroxychloroquine |
| T4 | 138-149 | NCBITaxon:11118 | denotes | Coronavirus |
| T5 | 159-167 | SP_7 | denotes | COVID-19 |
| T6 | 258-276 | CHEBI:5801 | denotes | Hydroxychloroquine |
| T7 | 258-276 | DG_20 | denotes | Hydroxychloroquine |
| T8 | 258-276 | CHEBI:5801 | denotes | Hydroxychloroquine |
| T9 | 331-344 | NCBITaxon:11118 | denotes | coronaviruses |
| T10 | 359-369 | SP_7 | denotes | SARS-CoV-2 |
| T11 | 395-400 | NCBITaxon:10239 | denotes | virus |
| T12 | 425-434 | GO:0005768 | denotes | endosomal |
| T13 | 451-456 | NCBITaxon:10239 | denotes | virus |
| T14 | 457-468 | GO:0061025 | denotes | cell fusion |
| T15 | 490-495 | NCBITaxon:10239 | denotes | viral |
| T16 | 490-495 | GO:0019012 | denotes | viral |
| T17 | 496-503 | GO:0009986 | denotes | surface |
| T18 | 553-571 | CHEBI:5801 | denotes | hydroxychloroquine |
| T19 | 553-571 | DG_20 | denotes | hydroxychloroquine |
| T20 | 553-571 | CHEBI:5801 | denotes | hydroxychloroquine |
| T21 | 579-585 | UBERON:0002405 | denotes | immune |
| T22 | 586-596 | GO:0065007 | denotes | modulating |
| T23 | 703-707 | CHEBI:23888 | denotes | drug |
| T24 | 703-707 | CHEBI:23888 | denotes | drug |
| T25 | 743-751 | SP_10 | denotes | SARS-CoV |
| T26 | 854-862 | SP_7 | denotes | COVID-19 |
| T27 | 968-986 | CHEBI:5801 | denotes | hydroxychloroquine |
| T28 | 968-986 | DG_20 | denotes | hydroxychloroquine |
| T29 | 968-986 | CHEBI:5801 | denotes | hydroxychloroquine |
| T30 | 1013-1021 | SP_7 | denotes | COVID-19 |
| T31 | 1045-1055 | SP_7 | denotes | SARS-CoV-2 |
| T32 | 1115-1123 | SP_7 | denotes | COVID-19 |
| T33 | 1204-1212 | SP_7 | denotes | COVID-19 |
| T34 | 1383-1401 | CHEBI:5801 | denotes | hydroxychloroquine |
| T35 | 1383-1401 | DG_20 | denotes | hydroxychloroquine |
| T36 | 1383-1401 | CHEBI:5801 | denotes | hydroxychloroquine |
| T37 | 1441-1451 | SP_7 | denotes | SARS-CoV-2 |
| T38 | 1517-1525 | SP_7 | denotes | COVID-19 |
| T39 | 1591-1599 | SP_7 | denotes | COVID-19 |
| T40 | 1624-1639 | UBERON:0003693 | denotes | rhinopharyngeal |
| T41 | 1643-1656 | UBERON:0001852 | denotes | oropharyngeal |
| T42 | 1666-1676 | SP_7 | denotes | SARS-CoV-2 |
| T43 | 1778-1786 | SP_7 | denotes | COVID-19 |
| T44 | 2064-2082 | CHEBI:5801 | denotes | hydroxychloroquine |
| T45 | 2064-2082 | DG_20 | denotes | hydroxychloroquine |
| T46 | 2064-2082 | CHEBI:5801 | denotes | hydroxychloroquine |
| T47 | 2121-2139 | CHEBI:5801 | denotes | hydroxychloroquine |
| T48 | 2121-2139 | DG_20 | denotes | hydroxychloroquine |
| T49 | 2121-2139 | CHEBI:5801 | denotes | hydroxychloroquine |
| T50 | 2140-2151 | CHEBI:3638 | denotes | chloroquine |
| T51 | 2140-2151 | DG_10 | denotes | chloroquine |
| T52 | 2140-2151 | CHEBI:3638 | denotes | chloroquine |
| T53 | 2181-2186 | UBERON:0000948 | denotes | heart |
| T54 | 2220-2225 | UBERON:0000948 | denotes | heart |
| T55 | 2259-2264 | UBERON:0000948 | denotes | heart |
| T56 | 2285-2294 | CHEBI:77608 | denotes | diuretics |
| T57 | 2285-2294 | CHEBI:77608 | denotes | diuretics |
| T58 | 2306-2313 | CHEBI:17234 | denotes | glucose |
| T59 | 2306-2313 | CHEBI:17234 | denotes | glucose |
| T60 | 2313-2316 | CHEBI:14314 | denotes | -6- |
| T61 | 2313-2316 | CHEBI:14314 | denotes | -6- |
| T62 | 2316-2325 | CHEBI:18367 | denotes | phosphate |
| T63 | 2316-2325 | CHEBI:18367 | denotes | phosphate |
| T64 | 2421-2427 | UBERON:0002113 | denotes | kidney |
| T65 | 2474-2485 | UBERON:0002082 | denotes | ventricular |
| T66 | 2543-2555 | UBERON:0001016 | denotes | neurological |
| T67 | 2626-2630 | CHEBI:23888 | denotes | drug |
| T68 | 2626-2630 | CHEBI:23888 | denotes | drug |
| T69 | 2631-2635 | CHEBI:23888 | denotes | drug |
| T70 | 2631-2635 | CHEBI:23888 | denotes | drug |
| T71 | 2700-2705 | CHEBI:23888 | denotes | drugs |
| T72 | 2700-2705 | CHEBI:23888 | denotes | drugs |
| T73 | 3166-3184 | CHEBI:5801 | denotes | hydroxychloroquine |
| T74 | 3166-3184 | DG_20 | denotes | hydroxychloroquine |
| T75 | 3166-3184 | CHEBI:5801 | denotes | hydroxychloroquine |
| T76 | 3220-3238 | CHEBI:5801 | denotes | Hydroxychloroquine |
| T77 | 3220-3238 | DG_20 | denotes | Hydroxychloroquine |
| T78 | 3220-3238 | CHEBI:5801 | denotes | Hydroxychloroquine |
| T79 | 3312-3330 | CHEBI:5801 | denotes | hydroxychloroquine |
| T80 | 3312-3330 | DG_20 | denotes | hydroxychloroquine |
| T81 | 3312-3330 | CHEBI:5801 | denotes | hydroxychloroquine |
| T82 | 3389-3407 | CHEBI:5801 | denotes | hydroxychloroquine |
| T83 | 3389-3407 | DG_20 | denotes | hydroxychloroquine |
| T84 | 3389-3407 | CHEBI:5801 | denotes | hydroxychloroquine |
| T85 | 3512-3530 | CHEBI:5801 | denotes | hydroxychloroquine |
| T86 | 3512-3530 | DG_20 | denotes | hydroxychloroquine |
| T87 | 3512-3530 | CHEBI:5801 | denotes | hydroxychloroquine |
| T88 | 3803-3821 | CHEBI:5801 | denotes | Hydroxychloroquine |
| T89 | 3803-3821 | DG_20 | denotes | Hydroxychloroquine |
| T90 | 3803-3821 | CHEBI:5801 | denotes | Hydroxychloroquine |
| T91 | 3922-3930 | SP_7 | denotes | COVID-19 |
| T92 | 4233-4241 | SP_7 | denotes | COVID-19 |
| T93 | 4277-4295 | CHEBI:5801 | denotes | hydroxychloroquine |
| T94 | 4277-4295 | DG_20 | denotes | hydroxychloroquine |
| T95 | 4277-4295 | CHEBI:5801 | denotes | hydroxychloroquine |
| T96 | 4446-4450 | CHEBI:23888 | denotes | drug |
| T97 | 4446-4450 | CHEBI:23888 | denotes | drug |
| T98 | 4989-4997 | SP_7 | denotes | COVID-19 |
| T99 | 5018-5026 | SP_7 | denotes | COVID-19 |
| T100 | 5347-5355 | SP_7 | denotes | COVID-19 |
| T101 | 5372-5380 | SP_7 | denotes | COVID-19 |
| T102 | 5533-5541 | SP_7 | denotes | COVID-19 |
| T103 | 5672-5680 | SP_7 | denotes | COVID-19 |
| T104 | 6034-6044 | SP_7 | denotes | SARS-CoV-2 |
| T105 | 6107-6115 | SP_7 | denotes | COVID-19 |
| T106 | 6234-6242 | SP_7 | denotes | COVID-19 |
| T107 | 6298-6306 | SP_7 | denotes | COVID-19 |
| T108 | 6596-6604 | SP_7 | denotes | COVID-19 |
| T109 | 6649-6657 | SP_7 | denotes | COVID-19 |
| T110 | 6749-6757 | SP_7 | denotes | COVID-19 |
| T111 | 7047-7055 | SP_7 | denotes | COVID-19 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T1 | 425-434 | Body_part | denotes | endosomal | http://purl.org/sig/ont/fma/fma67180 |
| T2 | 457-461 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
| T3 | 504-512 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
| T4 | 2181-2186 | Body_part | denotes | heart | http://purl.org/sig/ont/fma/fma7088 |
| T5 | 2220-2225 | Body_part | denotes | heart | http://purl.org/sig/ont/fma/fma7088 |
| T6 | 2259-2264 | Body_part | denotes | heart | http://purl.org/sig/ont/fma/fma7088 |
| T7 | 2306-2313 | Body_part | denotes | glucose | http://purl.org/sig/ont/fma/fma82743 |
| T8 | 2421-2427 | Body_part | denotes | kidney | http://purl.org/sig/ont/fma/fma7203 |
| T9 | 2560-2566 | Body_part | denotes | mental | http://purl.org/sig/ont/fma/fma264279 |
| T10 | 3186-3189 | Body_part | denotes | Arm | http://purl.org/sig/ont/fma/fma24890 |
| T11 | 3212-3215 | Body_part | denotes | Arm | http://purl.org/sig/ont/fma/fma24890 |
| T12 | 4779-4782 | Body_part | denotes | arm | http://purl.org/sig/ont/fma/fma24890 |
| T13 | 4891-4894 | Body_part | denotes | arm | http://purl.org/sig/ont/fma/fma24890 |
| T14 | 5176-5179 | Body_part | denotes | arm | http://purl.org/sig/ont/fma/fma24890 |
| T15 | 5185-5188 | Body_part | denotes | arm | http://purl.org/sig/ont/fma/fma24890 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 2181-2186 | Body_part | denotes | heart | http://purl.obolibrary.org/obo/UBERON_0000948 |
| T2 | 2220-2225 | Body_part | denotes | heart | http://purl.obolibrary.org/obo/UBERON_0000948 |
| T3 | 2259-2264 | Body_part | denotes | heart | http://purl.obolibrary.org/obo/UBERON_0000948 |
| T4 | 2421-2427 | Body_part | denotes | kidney | http://purl.obolibrary.org/obo/UBERON_0002113 |
| T5 | 4779-4782 | Body_part | denotes | arm | http://purl.obolibrary.org/obo/UBERON_0001460 |
| T6 | 4891-4894 | Body_part | denotes | arm | http://purl.obolibrary.org/obo/UBERON_0001460 |
| T7 | 5176-5179 | Body_part | denotes | arm | http://purl.obolibrary.org/obo/UBERON_0001460 |
| T8 | 5185-5188 | Body_part | denotes | arm | http://purl.obolibrary.org/obo/UBERON_0001460 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 159-167 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T2 | 359-367 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T3 | 395-410 | Disease | denotes | virus infection | http://purl.obolibrary.org/obo/MONDO_0005108 |
| T4 | 401-410 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T5 | 743-751 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T6 | 854-862 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T7 | 886-895 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T8 | 1013-1021 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T9 | 1045-1053 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T10 | 1115-1123 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T11 | 1204-1212 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T12 | 1441-1449 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T13 | 1517-1525 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T14 | 1591-1599 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T15 | 1666-1674 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T16 | 1778-1786 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T17 | 2199-2209 | Disease | denotes | arrhythmia | http://purl.obolibrary.org/obo/MONDO_0007263 |
| T18 | 2211-2233 | Disease | denotes | ischemic heart disease | http://purl.obolibrary.org/obo/MONDO_0024644 |
| T19 | 2220-2233 | Disease | denotes | heart disease | http://purl.obolibrary.org/obo/MONDO_0005267 |
| T20 | 2235-2246 | Disease | denotes | retinopathy | http://purl.obolibrary.org/obo/MONDO_0005283 |
| T21 | 2248-2272 | Disease | denotes | congestive heart failure | http://purl.obolibrary.org/obo/MONDO_0005009 |
| T22 | 2259-2272 | Disease | denotes | heart failure | http://purl.obolibrary.org/obo/MONDO_0005252 |
| T23 | 2296-2302 | Disease | denotes | favism | http://purl.obolibrary.org/obo/MONDO_0001761 |
| T24 | 2341-2345 | Disease | denotes | G6PD | http://purl.obolibrary.org/obo/MONDO_0005775 |
| T25 | 2359-2367 | Disease | denotes | diabetes | http://purl.obolibrary.org/obo/MONDO_0005015 |
| T26 | 2413-2435 | Disease | denotes | chronic kidney disease | http://purl.obolibrary.org/obo/MONDO_0005300 |
| T27 | 2421-2435 | Disease | denotes | kidney disease | http://purl.obolibrary.org/obo/MONDO_0001343|http://purl.obolibrary.org/obo/MONDO_0005240 |
| T29 | 2486-2496 | Disease | denotes | arrhythmia | http://purl.obolibrary.org/obo/MONDO_0007263 |
| T30 | 2512-2534 | Disease | denotes | hematologic malignancy | http://purl.obolibrary.org/obo/MONDO_0002334|http://purl.obolibrary.org/obo/MONDO_0044881 |
| T32 | 2560-2574 | Disease | denotes | mental illness | http://purl.obolibrary.org/obo/MONDO_0002025 |
| T33 | 3922-3930 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T34 | 4233-4241 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T35 | 4989-4997 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T36 | 5018-5026 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T37 | 5347-5355 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T38 | 5372-5380 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T39 | 5533-5541 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T40 | 5672-5680 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T41 | 6034-6042 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T42 | 6107-6115 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T43 | 6234-6242 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T44 | 6298-6306 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T45 | 6596-6604 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T46 | 6649-6657 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T47 | 6749-6757 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T48 | 6758-6767 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T49 | 7047-7055 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 15-16 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T2 | 170-171 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T3 | 194-195 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T4 | 215-216 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T5 | 246-256 | http://purl.obolibrary.org/obo/BFO_0000030 | denotes | OBJECTIVES |
| T6 | 277-280 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T7 | 305-313 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
| T8 | 395-400 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T9 | 451-456 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T10 | 457-461 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T11 | 543-551 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
| T12 | 572-575 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T13 | 597-605 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
| T14 | 679-680 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T15 | 906-915 | http://purl.obolibrary.org/obo/BFO_0000030 | denotes | objective |
| T16 | 1245-1246 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T17 | 1264-1269 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
| T18 | 1614-1618 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | test |
| T19 | 1622-1623 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T20 | 1882-1883 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T21 | 1940-1942 | http://purl.obolibrary.org/obo/CLO_0050510 | denotes | 18 |
| T22 | 1950-1954 | http://purl.obolibrary.org/obo/UBERON_0003101 | denotes | male |
| T23 | 1950-1954 | http://www.ebi.ac.uk/efo/EFO_0000970 | denotes | male |
| T24 | 1958-1964 | http://purl.obolibrary.org/obo/UBERON_0003100 | denotes | female |
| T25 | 2181-2186 | http://purl.obolibrary.org/obo/UBERON_0000948 | denotes | heart |
| T26 | 2181-2186 | http://purl.obolibrary.org/obo/UBERON_0007100 | denotes | heart |
| T27 | 2181-2186 | http://purl.obolibrary.org/obo/UBERON_0015228 | denotes | heart |
| T28 | 2181-2186 | http://www.ebi.ac.uk/efo/EFO_0000815 | denotes | heart |
| T29 | 2220-2225 | http://purl.obolibrary.org/obo/UBERON_0000948 | denotes | heart |
| T30 | 2220-2225 | http://purl.obolibrary.org/obo/UBERON_0007100 | denotes | heart |
| T31 | 2220-2225 | http://purl.obolibrary.org/obo/UBERON_0015228 | denotes | heart |
| T32 | 2220-2225 | http://www.ebi.ac.uk/efo/EFO_0000815 | denotes | heart |
| T33 | 2259-2264 | http://purl.obolibrary.org/obo/UBERON_0000948 | denotes | heart |
| T34 | 2259-2264 | http://purl.obolibrary.org/obo/UBERON_0007100 | denotes | heart |
| T35 | 2259-2264 | http://purl.obolibrary.org/obo/UBERON_0015228 | denotes | heart |
| T36 | 2259-2264 | http://www.ebi.ac.uk/efo/EFO_0000815 | denotes | heart |
| T37 | 2421-2427 | http://purl.obolibrary.org/obo/UBERON_0002113 | denotes | kidney |
| T38 | 2421-2427 | http://www.ebi.ac.uk/efo/EFO_0000927 | denotes | kidney |
| T39 | 2421-2427 | http://www.ebi.ac.uk/efo/EFO_0000929 | denotes | kidney |
| T40 | 2896-2897 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T41 | 3186-3189 | http://www.ebi.ac.uk/efo/EFO_0001410 | denotes | Arm |
| T42 | 3190-3191 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T43 | 3212-3215 | http://www.ebi.ac.uk/efo/EFO_0001410 | denotes | Arm |
| T44 | 3216-3217 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | B |
| T45 | 3297-3298 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T46 | 3372-3373 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T47 | 3445-3447 | http://purl.obolibrary.org/obo/CLO_0050507 | denotes | 22 |
| T48 | 3453-3454 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T49 | 3494-3498 | http://purl.obolibrary.org/obo/CLO_0001236 | denotes | 2: A |
| T50 | 3594-3595 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T51 | 4186-4187 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T52 | 4551-4552 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T53 | 4779-4782 | http://www.ebi.ac.uk/efo/EFO_0001410 | denotes | arm |
| T54 | 4891-4894 | http://www.ebi.ac.uk/efo/EFO_0001410 | denotes | arm |
| T55 | 5107-5108 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T56 | 5176-5179 | http://www.ebi.ac.uk/efo/EFO_0001410 | denotes | arm |
| T57 | 5180-5181 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T58 | 5185-5188 | http://www.ebi.ac.uk/efo/EFO_0001410 | denotes | arm |
| T59 | 5189-5190 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | B |
| T60 | 5476-5477 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T61 | 5885-5888 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T62 | 5946-5951 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
| T63 | 6006-6007 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T64 | 6462-6471 | http://purl.obolibrary.org/obo/BFO_0000030 | denotes | objective |
| T65 | 6542-6543 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T66 | 6896-6897 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T67 | 6977-6978 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T68 | 7093-7094 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T69 | 7166-7167 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T70 | 7960-7963 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T71 | 8003-8004 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T72 | 8116-8119 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 47-65 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T2 | 295-304 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T3 | 504-512 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T4 | 533-542 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T5 | 553-571 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T6 | 643-652 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T7 | 703-707 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T8 | 968-986 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T9 | 1138-1140 | Chemical | denotes | II | http://purl.obolibrary.org/obo/CHEBI_74067 |
| T10 | 1264-1269 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
| T11 | 1323-1328 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T12 | 1383-1401 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T13 | 1950-1954 | Chemical | denotes | male | http://purl.obolibrary.org/obo/CHEBI_30780 |
| T14 | 2064-2082 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T15 | 2121-2139 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T16 | 2140-2151 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
| T17 | 2285-2294 | Chemical | denotes | diuretics | http://purl.obolibrary.org/obo/CHEBI_35498 |
| T18 | 2306-2313 | Chemical | denotes | glucose | http://purl.obolibrary.org/obo/CHEBI_17234|http://purl.obolibrary.org/obo/CHEBI_4167 |
| T20 | 2316-2325 | Chemical | denotes | phosphate | http://purl.obolibrary.org/obo/CHEBI_18367|http://purl.obolibrary.org/obo/CHEBI_26020|http://purl.obolibrary.org/obo/CHEBI_35780|http://purl.obolibrary.org/obo/CHEBI_43474 |
| T24 | 2626-2630 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T25 | 2631-2635 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T26 | 2700-2705 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T27 | 3166-3184 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T28 | 3312-3330 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T29 | 3389-3407 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T30 | 3512-3530 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T31 | 4277-4295 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T32 | 4446-4450 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T33 | 5946-5951 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
| T34 | 6395-6400 | Chemical | denotes | alpha | http://purl.obolibrary.org/obo/CHEBI_30216 |
| T35 | 7986-7992 | Chemical | denotes | Letter | http://purl.obolibrary.org/obo/CHEBI_6446 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 457-468 | http://purl.obolibrary.org/obo/GO_0140253 | denotes | cell fusion |
| T2 | 457-468 | http://purl.obolibrary.org/obo/GO_0045026 | denotes | cell fusion |
| T3 | 457-468 | http://purl.obolibrary.org/obo/GO_0000768 | denotes | cell fusion |
| T4 | 457-468 | http://purl.obolibrary.org/obo/GO_0000747 | denotes | cell fusion |
| T5 | 473-486 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
| T6 | 2187-2193 | http://purl.obolibrary.org/obo/GO_0048511 | denotes | rhythm |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-14 | Sentence | denotes | PROTECT Trial: |
| T2 | 15-169 | Sentence | denotes | A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): |
| T3 | 170-245 | Sentence | denotes | A structured summary of a study protocol for a randomized controlled trial. |
| T4 | 246-257 | Sentence | denotes | OBJECTIVES: |
| T5 | 258-370 | Sentence | denotes | Hydroxychloroquine has shown to have antiviral activity in vitro against coronaviruses, specifically SARS-CoV-2. |
| T6 | 371-513 | Sentence | denotes | It is believed to block virus infection by increasing endosomal pH required for virus cell fusion and glycosylation of viral surface proteins. |
| T7 | 514-755 | Sentence | denotes | In addition to its antiviral activity, hydroxychloroquine has an immune-modulating activity that may synergistically enhance its antiviral effect in vivo, making it a potentially promising drug for the prevention and the cure of SARS-CoV-19. |
| T8 | 756-896 | Sentence | denotes | However, randomized controlled trials are needed to assess whether it can be used safely to treat COVID-19 patients or to prevent infection. |
| T9 | 897-1222 | Sentence | denotes | The main objective of the present study is to evaluate the efficacy of hydroxychloroquine for (I) the prevention of COVID-19 or related symptoms in SARS-CoV-2-exposed subjects, such as as household members/contacts of COVID-19 patients and (II) the treatment of early-phase asymptomatic or paucisymptomatic COVID-19 patients. |
| T10 | 1223-1236 | Sentence | denotes | TRIAL DESIGN: |
| T11 | 1237-1336 | Sentence | denotes | This is a controlled, open label, cluster-randomized, superiority trial with parallel group design. |
| T12 | 1337-1426 | Sentence | denotes | Subjects will be randomized either to receive hydroxychloroquine or to observation (2:1). |
| T13 | 1427-1826 | Sentence | denotes | PARTICIPANTS: SARS-CoV-2-exposed subjects, including household members and/or contacts of COVID-19 patients and healthcare professionals (Group 1) or patients with COVID-19 (positive PCR test on a rhinopharyngeal or oropharyngeal swab for SARS-CoV-2), asymptomatic or paucisymptomatic in home situations who are not undergoing treatment with any anti COVID-19 medication (Group 2), will be enrolled. |
| T14 | 1827-1912 | Sentence | denotes | Paucisymptomatic patients are defined as patients with a low number of mild symptoms. |
| T15 | 1913-2734 | Sentence | denotes | All subjects must be aged ≥18 years, male or female, must be willing and able to give informed consent and must not have any contraindications to take hydroxychloroquine (intolerance or previous toxicity for hydroxychloroquine/chloroquine, bradycardia or reduction in heart rhythm with arrhythmia, ischemic heart disease, retinopathy, congestive heart failure with use of diuretics, favism or glucose-6-phosphate dehydrogenase (G6PD) deficiency, diabetes type 1, major comorbidities such as advanced chronic kidney disease or dialysis therapy, known history of ventricular arrhythmia, any oncologic/hematologic malignancy, severe neurological and mental illness, current use of medications with known significant drug-drug interactions, and known prolonged QT syndrome or current use of drugs with known QT prolongation). |
| T16 | 2735-2864 | Sentence | denotes | The study is monocentric and will be conducted at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS. |
| T17 | 2865-2942 | Sentence | denotes | Subjects will be enrolled from a large epidemic region (North-Central Italy). |
| T18 | 2943-3062 | Sentence | denotes | The Public Health Departments of several Italian regions will collaborate by identifying potentially eligible subjects. |
| T19 | 3063-3091 | Sentence | denotes | INTERVENTION AND COMPARATOR: |
| T20 | 3092-3219 | Sentence | denotes | The participants will be randomized (2:1 randomization) to receive either hydroxychloroquine (Arm A) or to Observation (Arm B). |
| T21 | 3220-3288 | Sentence | denotes | Hydroxychloroquine will be administered with the following schedule: |
| T22 | 3289-3296 | Sentence | denotes | Group1: |
| T23 | 3297-3487 | Sentence | denotes | A loading dose hydroxychloroquine 400 mg twice daily on day 1, followed by a weekly dose of hydroxychloroquine 200 mg twice daily on days 8, 15 and 22, for a total of one month of treatment. |
| T24 | 3488-3496 | Sentence | denotes | Group 2: |
| T25 | 3497-3614 | Sentence | denotes | A loading dose hydroxychloroquine 400 mg twice daily on day 1 followed by 200 mg twice daily for a total of 5-7 days. |
| T26 | 3615-3802 | Sentence | denotes | The comparator in this trial is observation given that currently neither treatment is administered to asymptomatic or paucisymptomatic subjects, nor prophylaxis is available for contacts. |
| T27 | 3803-3883 | Sentence | denotes | Hydroxychloroquine will be shipped to subjects within 24 hours of randomization. |
| T28 | 3884-4046 | Sentence | denotes | Given the extraordinary nature of the COVID-19 pandemic, only telephonic interviews will be carried out and electronic Patient Reported Outcomes (ePRO) completed. |
| T29 | 4047-4328 | Sentence | denotes | During treatment, each subject will be contacted every other day for the first week and weekly thereafter (Group 2) or weekly (Group 1) by a study physician to assess early onset of any COVID-19 symptom or any adverse reaction to hydroxychloroquine and to check subject compliance. |
| T30 | 4329-4513 | Sentence | denotes | Furthermore, all subjects will receive periodic ePROs which may be completed through smartphone or tablets to record drug self-administration and onset of any symptom or adverse event. |
| T31 | 4514-4615 | Sentence | denotes | All subjects will be followed up for a total of 6 months by periodic telephonic interviews and ePROs. |
| T32 | 4616-4630 | Sentence | denotes | MAIN OUTCOMES: |
| T33 | 4631-4927 | Sentence | denotes | The primary endpoint/outcome measure for this trial is: for Group 1, the proportion of subjects who become symptomatic and/or swab-positive in each arm within one month of randomization; for Group 2, the proportion of subjects who become swab-negative in each arm within 14 days of randomization. |
| T34 | 4928-4942 | Sentence | denotes | RANDOMIZATION: |
| T35 | 4943-5191 | Sentence | denotes | All household members and/or contacts of each COVID-19 index case, and the COVID-19 patient himself/herself, fulfilling all inclusion criteria will be grouped into a single cluster and this cluster will be randomized (2:1) to either arm A or arm B. |
| T36 | 5192-5262 | Sentence | denotes | Information on each subject will be recorded in specific data records. |
| T37 | 5263-5368 | Sentence | denotes | Randomization lists will be stratified according to the following factors regarding COVID-19 index cases: |
| T38 | 5369-5371 | Sentence | denotes | 1. |
| T39 | 5372-5461 | Sentence | denotes | COVID-19 risk level on the basis of province of residence (high vs. low/intermediate); 2. |
| T40 | 5462-5516 | Sentence | denotes | Index case is a healthcare professional (yes vs.no) 3. |
| T41 | 5517-5742 | Sentence | denotes | Index case with COVID-19 treatment (yes vs. no) An independent statistician not otherwise involved in the trial will generate the allocation sequence, and COVID-19 response teams will be unaware of the allocation of clusters. |
| T42 | 5743-5843 | Sentence | denotes | Randomization will be performed through an interactive web-based electronic data-capturing database. |
| T43 | 5844-5906 | Sentence | denotes | An Independent Data Monitoring Committee has been established. |
| T44 | 5907-5926 | Sentence | denotes | BLINDING (MASKING): |
| T45 | 5927-5952 | Sentence | denotes | This study is open label. |
| T46 | 5953-5992 | Sentence | denotes | NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): |
| T47 | 5993-6153 | Sentence | denotes | For Group 1, a sample size of about 2000 SARS-CoV-2-exposed subjects such as household members and/or contacts of COVID-19 patients will take part in the study. |
| T48 | 6154-6336 | Sentence | denotes | Assuming around 1.5-2.0 asymptomatic household members and/or contacts for each COVID-19 patient, we expect to identify approximately 1000-1300 COVID-19 index cases to be randomized. |
| T49 | 6337-6419 | Sentence | denotes | An interim analysis on efficacy is planned using standard alpha-spending function. |
| T50 | 6420-6708 | Sentence | denotes | For Group 2, sufficient power for primary objective (negative swab within 14 days of randomization) will be reached given a sample size of 300 asymptomatic or paucisymptomatic COVID-19 subjects in home situations not treated for COVID-19 (25%-30% of about 1000-1300 expected index cases). |
| T51 | 6709-7010 | Sentence | denotes | Since up to date reduced evidence about COVID-19 infection epidemiology, the continuous update of diagnostic and therapeutic approaches, the sample size estimation could be updated after a one third of population will be recruited and eventually modified according to a substantial protocol amendment. |
| T52 | 7011-7076 | Sentence | denotes | An interim analysis at 100 enrolled COVID-19 patients is planned. |
| T53 | 7077-7241 | Sentence | denotes | We have planned a Generalized Estimating Equation analysis, which is more efficient than a cluster level analysis, to take advantage of subject-specific covariates. |
| T54 | 7242-7325 | Sentence | denotes | The above reported sample size analysis is therefore to be considered conservative. |
| T55 | 7326-7339 | Sentence | denotes | TRIAL STATUS: |
| T56 | 7340-7424 | Sentence | denotes | The current version of the PROTECT trial protocol is 'Final version, 15 April 2020'. |
| T57 | 7425-7459 | Sentence | denotes | The study started on 9th May 2020. |
| T58 | 7460-7508 | Sentence | denotes | The first patient was enrolled on 14th May 2020. |
| T59 | 7509-7564 | Sentence | denotes | Recruitment is expected to last through September 2020. |
| T60 | 7565-7584 | Sentence | denotes | TRIAL REGISTRATION: |
| T61 | 7585-7645 | Sentence | denotes | The PROTECT trial is registered in the EudraCT database (no. |
| T62 | 7646-7740 | Sentence | denotes | 2020-001501-24) and in ClinicalTrials.gov ( NCT04363827 ), date of registration 24 April 2020. |
| T63 | 7741-7755 | Sentence | denotes | FULL PROTOCOL: |
| T64 | 7756-7872 | Sentence | denotes | The full PROTECT protocol is attached as an additional file, accessible from the Trials website (Additional file 1). |
| T65 | 7873-8096 | Sentence | denotes | In the interests of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol (Protocol final version, 15th April 2020). |
| T66 | 8097-8177 | Sentence | denotes | The study protocol has been reported in accordance with Standard Protocol Items: |
| T67 | 8178-8269 | Sentence | denotes | Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2). |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 3 | 47-65 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
| 4 | 138-157 | Disease | denotes | Coronavirus disease | MESH:D018352 |
| 5 | 159-167 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 80 | 258-276 | Chemical | denotes | Hydroxychloroquine | MESH:D006886 |
| 81 | 331-344 | Species | denotes | coronaviruses | Tax:11118 |
| 82 | 359-369 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 83 | 395-410 | Disease | denotes | virus infection | MESH:D001102 |
| 84 | 553-571 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
| 85 | 743-751 | Species | denotes | SARS-CoV | Tax:694009 |
| 86 | 854-862 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 87 | 863-871 | Species | denotes | patients | Tax:9606 |
| 88 | 886-895 | Disease | denotes | infection | MESH:D007239 |
| 89 | 968-986 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
| 90 | 1013-1021 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 91 | 1045-1055 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 92 | 1115-1123 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 93 | 1124-1132 | Species | denotes | patients | Tax:9606 |
| 94 | 1204-1212 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 95 | 1213-1221 | Species | denotes | patients | Tax:9606 |
| 96 | 1383-1401 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
| 97 | 1427-1439 | Species | denotes | PARTICIPANTS | Tax:9606 |
| 98 | 1441-1451 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 99 | 1517-1525 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 100 | 1526-1534 | Species | denotes | patients | Tax:9606 |
| 101 | 1577-1585 | Species | denotes | patients | Tax:9606 |
| 102 | 1591-1599 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 103 | 1666-1676 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 104 | 1778-1786 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 105 | 1844-1852 | Species | denotes | patients | Tax:9606 |
| 106 | 1868-1876 | Species | denotes | patients | Tax:9606 |
| 107 | 2108-2116 | Disease | denotes | toxicity | MESH:D064420 |
| 108 | 2153-2164 | Disease | denotes | bradycardia | MESH:D001919 |
| 109 | 2199-2209 | Disease | denotes | arrhythmia | MESH:D001145 |
| 110 | 2211-2233 | Disease | denotes | ischemic heart disease | MESH:D003324 |
| 111 | 2235-2246 | Disease | denotes | retinopathy | MESH:D012164 |
| 112 | 2248-2272 | Disease | denotes | congestive heart failure | MESH:D006333 |
| 113 | 2296-2302 | Disease | denotes | favism | MESH:D005236 |
| 114 | 2306-2357 | Disease | denotes | glucose-6-phosphate dehydrogenase (G6PD) deficiency | MESH:D005955 |
| 115 | 2359-2367 | Disease | denotes | diabetes | MESH:D003920 |
| 116 | 2413-2435 | Disease | denotes | chronic kidney disease | MESH:D051436 |
| 117 | 2474-2496 | Disease | denotes | ventricular arrhythmia | MESH:D001145 |
| 118 | 2512-2534 | Disease | denotes | hematologic malignancy | MESH:D019337 |
| 119 | 2560-2574 | Disease | denotes | mental illness | MESH:D002908 |
| 120 | 2660-2681 | Disease | denotes | prolonged QT syndrome | MESH:D008133 |
| 121 | 2717-2732 | Disease | denotes | QT prolongation | MESH:D008133 |
| 122 | 2832-2850 | Disease | denotes | la Cura dei Tumori | MESH:D049310 |
| 123 | 3096-3108 | Species | denotes | participants | Tax:9606 |
| 124 | 3166-3184 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
| 125 | 3220-3238 | Chemical | denotes | Hydroxychloroquine | MESH:D006886 |
| 126 | 3312-3330 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
| 127 | 3389-3407 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
| 128 | 3512-3530 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
| 129 | 3803-3821 | Chemical | denotes | Hydroxychloroquine | MESH:D006886 |
| 130 | 3922-3930 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 131 | 4003-4010 | Species | denotes | Patient | Tax:9606 |
| 132 | 4233-4241 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 133 | 4277-4295 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
| 134 | 4989-4997 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 135 | 5018-5026 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 136 | 5027-5034 | Species | denotes | patient | Tax:9606 |
| 137 | 5347-5355 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 138 | 5372-5380 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 139 | 5533-5541 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 140 | 5672-5680 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 141 | 6034-6044 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 142 | 6107-6115 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 143 | 6116-6124 | Species | denotes | patients | Tax:9606 |
| 144 | 6234-6242 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 145 | 6243-6250 | Species | denotes | patient | Tax:9606 |
| 146 | 6298-6306 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 147 | 6596-6604 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 148 | 6649-6657 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 149 | 6749-6757 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 150 | 6758-6767 | Disease | denotes | infection | MESH:D007239 |
| 151 | 7047-7055 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 152 | 7056-7064 | Species | denotes | patients | Tax:9606 |
| 153 | 7470-7477 | Species | denotes | patient | Tax:9606 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 2153-2164 | Phenotype | denotes | bradycardia | http://purl.obolibrary.org/obo/HP_0001662 |
| T2 | 2199-2209 | Phenotype | denotes | arrhythmia | http://purl.obolibrary.org/obo/HP_0011675 |
| T3 | 2235-2246 | Phenotype | denotes | retinopathy | http://purl.obolibrary.org/obo/HP_0000488 |
| T4 | 2248-2272 | Phenotype | denotes | congestive heart failure | http://purl.obolibrary.org/obo/HP_0001635 |
| T5 | 2413-2435 | Phenotype | denotes | chronic kidney disease | http://purl.obolibrary.org/obo/HP_0012622 |
| T6 | 2474-2496 | Phenotype | denotes | ventricular arrhythmia | http://purl.obolibrary.org/obo/HP_0004308 |
hydroxychloroquine
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 2153-2164 | Phenotype | denotes | bradycardia | http://purl.obolibrary.org/obo/HP_0001662 |
| T2 | 2199-2209 | Phenotype | denotes | arrhythmia | http://purl.obolibrary.org/obo/HP_0011675 |
| T3 | 2235-2246 | Phenotype | denotes | retinopathy | http://purl.obolibrary.org/obo/HP_0000488 |
| T4 | 2248-2272 | Phenotype | denotes | congestive heart failure | http://purl.obolibrary.org/obo/HP_0001635 |
| T5 | 2413-2435 | Phenotype | denotes | chronic kidney disease | http://purl.obolibrary.org/obo/HP_0012622 |
| T6 | 2474-2496 | Phenotype | denotes | ventricular arrhythmia | http://purl.obolibrary.org/obo/HP_0004308 |